AACR: Study Looks at Predictors of UV Radiation Exposure in High School Students
via HealthDayTHURSDAY, April 23, 2026 -- For high school students, perceived higher costs of ultraviolet radiation (UVR) protection and greater tanning reward are independent predictors of lower sun-safe behavior, according to a study published online April 21 in Cancer, Epidemiology, Biomarkers & Prevention to coincide with the annual meeting of the American Association for Cancer Research, held from April 17 to 22 in San Diego.
Omar U. Anwar, from the Lombardi Comprehensive Cancer Center in Washington, D.C., and colleagues used data from 2,105 students enrolled in the Sun-safe Habits Intervention and Education cluster-randomized trial conducted in Utah high schools from 2021 to 2023 to examine associations between perceptions of the costs of UVR protections, the rewards of tanning, and engagement in UVR-protective behaviors.
The researchers found that students engaged in fewer UVR-protective behaviors if they perceived higher costs of UVR protection and greater rewards of tanning. A lower knowledge of UVR safety, higher perceived protection cost, and greater tanning reward independently predicted low sun-safe behavior in an adjusted model.
"This study drives home the importance of reaching people early in life with more effective skin cancer prevention strategies that resonate, and working with communities to help lower the cancer burden," Anwar said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-24 02:02
Read more
- Judge Allows Abortion Pill, Mifepristone, To Continue Being Mailed for Now
- Surgery for Early-Stage NSCLC Yields Similar Outcomes in Octogenarians, Younger Patients
- Cheap Children's Clothing Tainted With Lead, Study Says
- U.S. Plans Tariffs up to 100% on Some Brand-Name Drugs
- SaFETy Score in ED Predicts 12-Month Risk for Firearm Violence
- U.S. FDA Grants Full Approval of Kite’s Tecartus for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions